2022 European Medicines Agency annual report on independence

2021 European Medicines Agency annual report on independence

Human medicines European public assessment report (EPAR): Refixia, nonacog beta pegol, Hemophilia B, Date of authorisation: 02/06/2017, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene), pomalidomide, Multiple Myeloma, Date of authorisation: 05/08/2013, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Lojuxta, lomitapide, Hypercholesterolemia, Date of authorisation: 31/07/2013, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Flebogamma DIF (previously Flebogammadif), human normal immunoglobulin, Mucocutaneous Lymph Node Syndrome;Guillain-Barre Syndrome;Bone Marrow Transplantation;Purpura, Thrombocytopenic, Idiopathic;Immunologic Deficiency Syndromes, Date of authorisation: 23/07/2007, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Growth and Development, Date of authorisation: 11/01/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Mozobil, plerixafor, Multiple Myeloma;Hematopoietic Stem Cell Transplantation;Lymphoma, Date of authorisation: 30/07/2009, Revision: 23, Status: Authorised

Notification on arrangements for requesting EMA certificates through urgent and standard procedure for December 2023

Certification of medicinal products